Boundary Cap Neural Crest Stem Cells Promote Survival of Mutant SOD1 Motor Neurons by Tanya Aggarwal et al.
ORIGINAL ARTICLE
Boundary Cap Neural Crest Stem Cells Promote
Survival of Mutant SOD1 Motor Neurons
Tanya Aggarwal1 & Jan Hoeber1 & Patrik Ivert1 & Svitlana Vasylovska1 &
Elena N Kozlova1
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract ALS is a devastating disease resulting in degenera-
tion of motor neurons (MNs) in the brain and spinal cord. The
survival of MNs strongly depends on surrounding glial cells
and neurotrophic support from muscles. We previously dem-
onstrated that boundary cap neural crest stem cells (bNCSCs)
can give rise to neurons and glial cells in vitro and in vivo and
have multiple beneficial effects on co-cultured and co-
implanted cells, including neural cells. In this paper, we inves-
tigate if bNCSCs may improve survival of MNs harboring a
mutant form of human SOD1 (SOD1G93A) in vitro under nor-
mal conditions and oxidative stress and in vivo after implan-
tation to the spinal cord. We found that survival of SOD1G93A
MNs in vitro was increased in the presence of bNCSCs under
normal conditions as well as under oxidative stress. In addi-
tion, when SOD1G93A MN precursors were implanted to the
spinal cord of adult mice, their survival was increased when
they were co-implanted with bNCSCs. These findings show
that bNCSCs support survival of SOD1G93A MNs in normal
conditions and under oxidative stress in vitro and improve
their survival in vivo, suggesting that bNCSCs have a potential
for the development of novel stem cell-based therapeutic ap-
proaches in ALS models.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive, neuro-
degenerative disorder affecting primarily upper and lower mo-
tor neurons (MNs), and usually leading to the death of the
patient, most commonly due to respiratory failure. The gluta-
mate signaling antagonist Riluzole has a measurable positive
effect on disease progression and is relatively free of side
effects. Riluzole acts by attenuating excitotoxic impact on
endangeredMNs, and is currently the only available approved
ALS treatment, but offers not more than a few months extend-
ed life expectancy [1]. Riluzole exerts a wide range of neural
effects which can influence neuronal activity and survival,
although the mechanism of action still remains controversial
[2]. About 10% of ALS cases are familial and several genetic
mutations linked to this group of patients have been identified.
Mutations in superoxide dismutase (SOD)1 are found in about
20% of familial cases and in a few percent of sporadic ALS
cases [3]. SOD1 is an enzyme that helps in the catalysis of
dismutation of superoxide to molecular oxygen and hydrogen
peroxide [3]. The association between mutant SOD1 and ALS
onset, and the subsequent generation of transgenic animals
harboring human mutant and non-mutant forms of SOD1,
have played a pivotal role and remains a cornerstone in re-
search on the pathogenesis of ALS and in the search for novel
therapeutic treatment of this disease [3]. To date, more than
150 SOD1 mutations have been identified and SOD1G93A is
the most widely studied model for ALS pathogenesis [3].
Mutant SOD1 affects not only intrinsic properties of MNs,
but also results in a neurotoxic astroglial phenotype, inducing
degeneration of wild type MNs in vitro [4–7] and in vivo after
transplantation into the spinal cord of rats [8]. Furthermore,
astrocytes from patients with sporadic as well as familial ALS
exert a toxic effect on primaryMNs in vitro [9, 10]. Conversely,
deletion of mutant SOD1 in astrocytes of transgenic mice
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significantly delays disease progression [11]. Wild type astro-
cytes release factors that promote survival of co-cultured mu-
tant SOD1 MNs [12]. Implantation of stem/progenitor cell-
derived astrocytes into the spinal cord or ventricular system
of transgenic mice with mutant SOD1 promotes MN survival
and delays disease progression [13, 14].
Boundary cap neural crest stem cells (bNCSCs) is a transient
neural crest-derived group of cells that are located at the dorsal
root entry zone (DREZ) [15]. These cells self-renew and show
multipotency in culture and are able to differentiate into sensory
neurons and Schwann cells in vitro and in vivo [15], as well as
into astrocytes in vitro and after transplantation into the imma-
ture mouse brain [16]. We have previously shown remarkable,
beneficial effects of bNCSCs on co-cultured [17, 18] and co-
implanted pancreatic beta-cells [19], as well as excitotoxically
challenged spinal cord neurons in vitro (unpublished observa-
tion). Interestingly, another type of NCSCs, the hair follicle
stem cells, did not have corresponding positive effects on co-
cultured cells [20].
These findings prompted us to test if bNCSCs have a ben-
e f i c i a l e f f ec t on co-cu l tu red and co- implan ted
SOD1G93AMNs, generated from SOD1G93A mouse embryon-
ic stem cells (mESCs). These cell lines express green fluores-
cent protein (GFP) under the control of the promoter for the
MN specific transcription factor HB9 (HB9::GFP cells),
allowing their identification after directed differentiation to
MN progenitors [21]. Furthermore, the survival of MN from
the same SOD1G93A mESC line was previously analyzed
in vitro under normal conditions [21]. Here, we investigate
their survival in normal conditions and under oxidative stress
and the effect of bNCSCs on SOD1G93A MN survival.
Generation of MNs from mESCs results also in abundant
generation of astrocytes. These cells express glutamate aspar-
tate transporter (GLAST) and can be identified by anti-
GLAST antibodies [22]. To exclude the negative effect from
surrounding SOD1G93A astrocytes on SOD1G93A MNs, we
used magnetic activated cell sorting (MACS) to eliminate
GLAST-positive cells from SOD1G93A mESC cultures. To
compare the effect of bNCSCs on SOD1G93A MN survival
with mESC derived astrocytes, we used astrocytes differenti-
ated from a non-SOD1 mutated glial fibrillary acidic protein
(GFAP)::CD14 mESC line [23].
Our findings show that bNCSCs exert a significant survival
promoting effect on co-cultured and co-implanted SOD1G93A
MNs.
Material and methods
Mouse embryonic stem cell (mESC) cultures
Mouse embryonic stem cell (mESC) lines harboring human
wild type SOD1 (SOD1WT) or mutant SOD1 (SOD1G93A)
were a kind gift from Dr. Kevin Eggan (Harvard Stem Cell
Institute). The risk of tumor formation for implanted cells
from low passages is minimal. These cell lines carry green
fluorescent protein (GFP) under the control of the promoter
for theMN specific transcription factor HB9 (HB9::GFP cells)
[21]. We used the SOD1WT and SOD1G93A mESC lines to
derive GFP+ MNs.
For MN differentiation, a previously published protocol
with small modifications was used [24]. Cells were cultured
in ADFNB medium consisting of Advanced D-MEM/
F12:Neurobasal (1:1), 1x GlutaMAX supplement
(Invitrogen), 1x B27 supplement (Invitrogen), 1x N2 supple-
ment (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma) to
form embryoid bodies (EBs), and supplemented with
0.1 μM of retinoic acid (RA, Sigma) and 0.5 μM of sonic
hedgehog (Shh) agonist Ag1.3 (Curis) every other day. After
7 days of pre-differentiation, EBs were subjected to MACS
(see below), and thereafter either cultured alone, co-cultured
with bNCSCs, or with mESC-derived astrocytes.
For in vitro MN differentiation, EBs were enzymatically
dissociated with TrypLE™ Express (Gibco) and seeded on
pre-coated coverslips with 0.01% poly-l-ornithine (Sigma)
followed by 10 μg/mL laminin (Sigma). Cells were seeded
at a density of 5×104 cells/coverslip in 24 well plates with
ADFNB cell medium supplemented with 10 ng/mL of CNTF
(Miltenyi Biotec) and GDNF (Miltenyi Biotec). 50% of the
mediumwas replaced with fresh medium every other day until
the cultures were fixed in 4% paraformaldehyde in phosphate
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 100 mM
Na2HPO4, 18 mM KH2PO4) at the indicated time points.
bNCSC culture
bNCSCs were generated from transgenic mice harboring red
fluorescent protein (RFP) under the universal actin promoter
[25] according to previously published protocols [15, 26].
Neurospheres from passages 4 to 5 were trypsinized to obtain
single cell suspensions for MACS for subsequent co-culture
and co-implantation with SOD1G93A MNs.
Derivation of astrocytes fromGFAP::CD14 mESC culture
Astrocytes were generated from GFAP::CD14 mESCs (kind
gift from Dr. Ivo Lieberam, Kings College, London), using
MACS as has been previously described [23] with minor
modifications. At day 7 of differentiation, the EBs were re-
plated into T75 flasks (Sarstedt) pre-coated with 10 μg/mL
laminin and cultured until day 12 in ADFNB medium. The
monolayer formed by EBs was treated with TrypLE™
Express on day 12 and a single cell suspension was prepared
for MACS. Anti-CD14 antibody conjugated with magnetic
microbeads was used according to the manufacturers protocol
(Miltenyi Biotec).
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Magnetic activated cell sorting (MACS)
Anti-GLAST (ACSA-1) antibodies were used for MACS ac-
cording to the manufacturers protocol (Miltenyi Biotec).
bNCSCs and GFAP::CD14 EBs were subjected to MACS to
obtain astrocyte cultures. SOD1G93A EBs were subjected to
MACS using anti-GLAST to deplete SOD1G93A MN cultures
from SOD1G93A astrocytes.
Culture suspensions containing around 3×106 cells were
labeled with anti-GLAST antibodies. Thereafter, anti-mouse
IgG magnetic microbeads (Miltenyi Biotec) were applied to
the cells for 15 minutes at 4 °C. Cells were re-suspended in
MACS buffer (Miltenyi Biotec) and the cell suspension was
loaded onto aMACS separation column (Miltenyi Biotec) and
placed in the magnetic field of a MACS separator.
The column was rinsed three times with 0.5 mL of MACS
buffer. In the case of the SOD1G93A cell line, the GLAST-
positive fraction was removed to minimize the influence of
SOD1G93A astrocytes on SOD1G93A MNs. For bNCSCs and
GFAP::CD14 EBs, the GLAST positive fractions were used
for the experiments.
For differentiation assays, 5×104 of SOD1G93A cells were
seeded on 0.01% poly-l-ornithine and 10 μg/mL laminin coat-
ed coverslips. In case of co-cultures, around 2 x 104 bNCSCs
or GFAP::CD14 mESC-derived astrocytes were seeded first
followed by SOD1G93A MNs.
Oxidative stress assay
Oxidative stress was induced by hydrogen peroxide (H2O2) in
SOD1WT MNs and SOD1G93A MNs plated alone or together
with bNCSCs. In addition, bNCSCs were treated alone with
H2O2 at similar concentrations to test their survival capacity
under these conditions. On day 4 of differentiation assay,
H2O2 (60 μM, 150 μM, 300 μM) was added for 3 hours to
the cultures. Thereafter, the coverslips were fixed and ana-
lyzed for MN or bNCSC survival (GFP-positive or RFP-
positive cells, respectively). For each condition at least three
experiments were performed.
Animals
Transplantations were performed in Crl:NU(NCr)-Foxn1nu
(nude; nu/nu) NMRI adult male mice (n=12), (body weight
25–35 g;Möllegaard and Bomholgard Breeding and Research
Centre, M&B A/S, Bomholt, Denmark, http://www.taconic.
com). The serial sections were from the spinal cords of six
animals− three of which received bNCSCs and SOD1G93A
MN precursors (treatment group) and three only SOD1G93A
MN precursors (control group) −were analyzed under
confocal microscope for MN survival and glial response. All
animal experiments were approved by the Local Ethical
Committee for Animal Experimentation, Uppsala, as
required by Swedish Legislation and in accordance with
European Union Directives.
Surgery
The animals were anesthetized by spontaneous inhalation of
Isoflurane. After onset of anesthesia the mouse was placed on
its stomach on a heating pad (36 °C) and the skin cleaned with
ethanol (70%). Following a procedure previously established
in rats [27], an incision was made in the midline of the neck
skin and local anesthetic (Xylocain©, 10 mg/ml) applied to
the wound. After blunt dissection of the superficial and deep
back muscles, the laminae of the cervical vertebrae were ex-
posed. The vertebra prominens (C7) was held fixed with a pair
of forceps, a partial laminectomy was made of vertebrae C3 to
C5, and the exposed meninges were gently opened. 4 μL (2
injections of 2 μL each, around 50 000 cells per mouse) of
equal proportion of bNCSCs and SOD1G93A MN precursors
were injected into the left spinal cord using a Hamilton syringe
with a metal needle (26 gauge) attached to a stereotactic frame
and connected to an infusion pump (KD Scientific Legato
130). For the control group an equal amount of cells contain-
ing only SOD1G93A MN precursors were injected. The needle
was kept in place for 2 minutes before removal. The wound
was closed in layers using ethilon nylon suture 6.0 and 4.0,
respectively. The animals were given 50 μl buprenorphine
(Temgesic©) subcutaneously every 12 hours for 3 days after
the operation.
Seven days after surgery the animals were re-anesthetized
with an intraperitoneal injection of a mixture of ketamine,
xylazine and acepromazine [28], and perfused via the left
ventricle with warm saline solution (~38 °C) followed by a
cold (~4 °C) fixative solution consisting of 4% formaldehyde
(vol/vol), 14% saturated picric acid (wt/vol) in phosphate
buffered saline (PBS; pH 7.35-7.45). The relevant part of the
cervical spinal cord was removed, placed in fixative solution
for 4 hours, and thereafter cryoprotected overnight in PBS
containing 15% sucrose. The following day the tissue was
placed in TissueTech™ and frozen in liquid nitrogen.
Transverse sections (14 μm) were cut on a cryostat, collected
on SuperFrost™ Plus slides (Menzel-Gläser, Braunschweig,
Germany), and processed for immunohistochemistry and mi-
croscopic analysis as described below.
Immunohistochemistry
Cells were fixed in 4% phosphate-buffered paraformaldehyde
at room temperature (RT) for 5 minutes, washed and left in
blocking solution (1% bovine serum albumin, 0.3% Triton
X-100 and 0.1% NaN3 in PBS) for 60 minutes, and then
incubated with primary antibodies overnight at 4 °C, followed
by the appropriate secondary antibodies for 1 hour at RT
(Table 1). During the final wash, the cells were incubated with
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Hoechst 33342 (1:10000; Invitrogen) to label cell nuclei, and
then mounted on a glass slide for analysis. bNCSC
neurospheres were fixed for 30 minutes, immersed in 15%
sucrose overnight, cryosectioned the next day and sections
processed for immunohistochemistry.
Transverse sections from the C3-5 spinal cord were pre-
incubated with blocking solution for 1 hr at RT and then in-
cubated overnight at 4 °C with primary antibodies for the
astroglial marker GFAP or microglia/macrophage marker
Iba1 followed by the appropriate secondary antibodies and
anti-GFP-FITC for 1 hour at RT (Table 1).
Microscopy and cell counting
Cells on coverslips and spinal cord cryosections were captured
using a 20× objective (NA 0.75) of a Nikon Eclipse E800
epifluorescence microscope equipped with a Nikon
DXM1200F CCD camera. For cultured cells, GFP and RFP
positive cells were counted manually for each condition. GFP
positive cells were counted in every 5th cryosection along the
length of the transplant area (ranging from ~0.8 to 1.5 mm
along the cranial-caudal axis between animals). Sections were
analysed using a Zeiss LSM700 or a Zeiss LSM780 confocal
laser scanning microscope. Images were captured using a LD
LCI Plan-Apochromat 20x (NA 0.8) or a LD C-Apochromat
40x W Corr (NA 1.1) objective.
Statistical Analysis
Datasets for oxidative stress and survival assays were ana-
lyzed using two-way ANOVA followed by the Bonferroni
multiple comparisons tests. MN survival was analyzed using
a two-tailed Students t-test. All statistical analyses were per-
formed in GraphPad Prism 5.04. The confidence interval was
stated at the 95% confidence level, placing statistical signifi-
cance at p<0.05.
Results
Improved survival of SOD1G93A MNs in vitro
Both SOD1WT and SOD1G93A mESC lines formed EBs with
abundant expression ofHB9::GFP and gave rise to GFP+ MN
precursors in culture (Supplementary Fig. 1).
bNCSCs neurospheres abundantly expressed RFP, the neural
crest stem cell marker SOX2 and GLAST (after MACS purifi-
cation), and continued to express RFP in differentiation assay in
co-culture and co-implants (Supplementary Figs. 2, 3 and 4).
Table 1 Antibodies used in the
study Antigen Host Catalog number Source Dilution
Primary
Human SOD1 misfolded Mouse MM-0070-2 Medimabs 1:100
GFAP Rabbit 2016-04 Dako 1:500
Iba1 Rabbit 019-19741 Wako 1:500
Beta-3-tubulin Mouse 32-2600 Invitrogen 1:500
ACSA-1 (GLAST) Mouse 130-095-822 Miltenyi Biotec 1:100
SOX2 Goat Sc-17320 Santa Cruz 1:200
GFP-FITC Goat ab6662 Abcam 1:250
Secondary
Alexa 647 Donkey α mouse A31571 Invitrogen 1:500
Alexa 647 Donkey α rabbit A31573 Invitrogen 1:500
FITC Donkey α goat 705-095-147 Jackson ImmunoResearch 1:200
AMCA 350 Donkey α rabbit 711-155-152 Jackson ImmunoResearch 1:100
Cy3 Donkey α mouse 715-165-151 Jackson ImmunoResearch 1:500
Fig. 1 Survival of SOD1WT and SOD1G93A MNs in vitro. The
SOD1G93A cell line shows a reduced MN survival compared to the
SOD1WT cell line between days 2 and 7. Asterisks indicate the level of
statistical significance by two-way ANOVA followed by Bonferroni
multiple comparison test (*** p < 0.001). Data shown is in mean ± SEM
of three independent experiments
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The poor survival of SOD1G93A MNs in vitro has been
compared to MNs derived from the HB9::GFP cell line in a
previous study [21]. Here we compare the survival of
SOD1G93A MNs with SOD1WT MNs to confirm that the re-
duced survival is due to the SOD1G93A mutation. Cells from
both cultures were subjected to differentiation assay and GFP+
MNs were counted after 2, 5 and 7 days of differentiation. The
number of MNs declined more rapidly in SOD1G93A cultures
at day 5 of differentiation (p<0.001) (Fig. 1).
During MN differentiation from mESCs, a population of
astrocytes is also present. Previous studies have shown a neg-
ative effect of SOD1G93A astrocytes on MNs [21]. We there-
fore examined if a reduction of the astrocyte population in
SOD1G93A cultures will improve MN survival and if co-
culture with bNCSCs, or with GFAP::CD14 astrocytes will
improve the survival of SOD1G93A MNs.
After reduction of the astrocyte population in SOD1G93A
cultures there was an approximate 75% increase in the number
of SOD1G93A MNs 12 hours after purification compared to
non-purified cell cultures (Fig. 2a; p<0.01). The survival of
SOD1G93A MNs was significantly increased in co-culture
with bNCSC by day 7 (Fig. 2b; p<0.01 and p<0.05), where-
as co-culture of SOD1G93AMNswithGFAP::CD14 astrocytes
did not affect MN survival (Fig. 2c).
We detected close contact between SOD1G93A MNs and
bNCSCs, but did not observe immunoreactivity for misfolded
SOD1 in bNCSCs, suggesting that aggregated SOD1 was not
transferred from SOD1G93A MNs to adjacent bNCSCs
(Fig. 3).
bNCSCs improve survival of SOD1G93A MNs in vitro
under oxidative stress
We compared the survival of SOD1G93A MNs and SOD1WT
MNs under oxidative stress. Survival of SOD1G93A MNs was
markedly decreased (p < 0.01 and p < 0.05) compared to
SOD1WT MNs, indicating that SOD1G93A MNs are more sus-
ceptible than wildtype MNs to oxidative stress (Fig. 4a). Co-
culture of SOD1G93A MNs with bNCSCs under oxidative
stress showed a significant increase in SOD1G93A MN surviv-
al compared to SOD1G93A MNs cultured alone (p<0.001 and
p<0.05, Fig. 4b).
We next tested if bNCSCs are susceptible to oxidative
stress under similar oxidative stress conditions and found no
effect of H2O2 exposure on the survival of bNCSCs in vitro
(Supplementary Fig. 3).
SOD1G93A MNs show increased survival in the presence
of bNCSCs in vivo
SOD1G93A MNs alone or together with bNCSCs were im-
planted into the left spinal cord of nude mice, and the survival
of implanted MNs was assessed one week after implantation.
In all animals which received SOD1G93A MN precursors to-
gether with bNCSCs, significantly more GFP+ SOD1G93A
MNs were detected compared to animals that received
SOD1G93A MN precursors alone (Student’s t-test, p< 0.05,
Fig. 5a). The surviving MNs were located in the proximity
of bNCSCs or localized as single cells in the spinal cord pa-
renchyma (Fig. 5b,c). Immunolabeling with the astrocytic
marker GFAP revealed that bNCSCs differentiated primarily
to GFAP positive cells (Fig. 5e).
The improved survival of MNs in the presence of bNCSCs
after implantation prompted us to investigate if bNCSCs affect
the glial response in the recipient spinal cord in the vicinity of
implanted MN precursors. As expected, there was an in-
creased immunolabeling for GFAP and Iba1 from the minor
injury at the injection site, but these changes were similar in
the two experimental groups (Fig. 5d,e). However. the glial
response for GFAP and Iba1 within the area where bNCSCs
Fig. 2 Increased survival of SOD1G93A MNs in vitro by removal of
SOD1G93A astrocytes and addition of bNCSC. Removal of astrocytes
from SOD1G93A cell cultures results in an increased number of
SOD1G93A MNs (a). Survival of SOD1G93A MNs increased when co-
cultured with bNCSCs (b). SOD1G93A MN survival showed no
improvement when co-cultured with GFAP::CD14 astrocytes (c).
Asterisks indicate the level of statistical significance by two-tailed
Student’s test (a) or two-way ANOVA (b) (** p < 0.01,*p < 0.05). Data
shown is in mean± SEM of three independent experiments
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were located seemed reduced compared to adjacent areas lack-
ing bNCSCs (Fig. 6a,b).
Discussion
There is an urgent need for novel therapeutic strategies with
enhanced effect for ALS patients. Here we show that bNCSCs
exert a significant survival promoting effect on SOD1G93A
MN in vitro as well as after co-implantation to the spinal cord.
Previously, we detected several beneficial effects of bNCSCs
on co-cultured and co-transplanted cells. Thus, bNCSCs
strongly increase proliferation of insulin producing beta-cells
in co-transplants of mouse pancreatic islets in streptozotocin
diabetic mice [19, 29], and in co-culture with beta-cells [17].
bNCSCs protect insulin-producing cells from cytokine in-
duced apoptosis in vitro [18], an effect which appears to re-
quire direct bNCSC- cell contact through catenin-cadherin
junctions [30]. Co-implantation of bNCSCs with mouse and
human pancreatic islets improves their survival after
Fig. 3 SOD1G93A MNs in the presence or absence of bNCSCs in vitro.
Co-cultured SOD1G93A cells (GFP) and bNCSCs (RFP) display close
contact on day 7 (a) and 9 (b), misfolded SOD1 was only detected in
SOD1G93A MNs. SOD1G93A MNs cultured alone show reduced survival
and the presence ofmisfolded SOD1 on day 7 (c) and day 9 (d). Scale bar:
50 μm
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transplantation and increases beta-cell proliferation, vascular-
ization of transplants and their re-innervation [29]. We also
found their survival supporting effect in spinal cord slice cul-
tures exposed to excitotoxic stress (unpublished observation).
The conditions for implanting healthy supportive cells into
the spinal cord of ALS patients imply that these cells will have
not only to survive in the harmful ALS environment, but also
exert beneficial effects on diseased MNs. For this reason we
have tested if bNCSCs are susceptible to oxidative stress and
found that they are resistant to exposure to hydrogen peroxide
in concentrations which significantly impair survival of
SOD1G93A MNs. We next examined whether bNCSCs are
“contaminated” with misfolded SOD1 from co-cultured
SOD1G93A MNs. ALS appears to begin focally at a random
location and progresses contiguously through two distinct
types of neuroanatomic propagation: contiguous propagation
through the extracellular matrix independent of synaptic con-
nections, and network propagation, which is dependent on
synaptic connections [31]. In many neurodegenerative disor-
ders misfolded proteins appear to contribute to disease pro-
gression [32]. Thus, the presence of misfolded SOD1 may
contribute to disease propagation in some forms of ALS
[33]. We detected immunoreactivity for misfolded SOD1 in
SOD1G93A MNs generated from SOD1G93A mESCs.
Although astrocytes co-cultured with SOD1G93A MNs have
been reported to be "contaminated" with aggregated SOD1
[34], we did not detect aggregated SOD1 in bNCSCs, sug-
gesting that they are resistant to relocation of misfolded
SOD1. Thus, bNCSCs display properties in vitro that may
be useful for disease modifying cell therapy in ALS.
We explored these properties in co-cultures of bNCSCs
with SOD1G93A MNs subjected to oxidative stress, and dem-
onstrated significantly increased SOD1G93A MN survival
compared to untreated SOD1G93A MN cultures. In agreement
with previous studies [11], we found that depletion of the
astrocyte population from SOD1G93A cultures, increases MN
survival. The addition of bNCSCs, but not healthy astrocytes,
to these cultures further improved the survival of SOD1G93A
MNs under both normal and oxidative stress conditions. This
finding provides additional evidence for the potency of
bNCSCs in supporting diseased SOD1G93A MNs. The im-
proved SOD1G93A MN survival coincided with the presence
of direct contacts between bNCSCs and SOD1G93A MNs,
suggesting that the positive effect of bNCSCs might be medi-
ated through intercellular connections, as was shown previ-
ously in bNCSC-beta-cell cultures [29]. We have also shown
that bNCSCs produce a broad range of trophic factors, as well
as Wnt-1 and matrix metalloproteinases [35]. This trophic
capacity, in co-operation with direct cell-cell interaction,
may explain the survival promoting effects of bNCSCs on
SOD1G93A MNs under stressful conditions in vitro.
Pre-differentiated neural cells are particularly vulnerable
during the initial period after implantation into the central
nervous system. At this stage environmental conditions that
support survival and differentiation of implanted cells are
likely to be critical for their subsequent integration into
neural circuits and long-term survival. We therefore focused
on the viability of SOD1G93A MNs alone, or in combina-
tion with bNCSCs, during the first week of their implanta-
tion. One week after implantation of SOD1G93A MN pre-
cursors to the spinal cord, only few surviving SOD1G93A
MNs were found. Survival of SOD1G93A MNs was, how-
ever, significantly increased when co-implanted with
bNCSCs, despite the fact that twice as many SOD1G93A
MN precursors were implanted alone compared to the num-
ber of SOD1G93A MN precursors co-implanted with
bNCSCs. These findings show that bNCSCs create envi-
ronmental conditions for SOD1G93A MNs, which support
their survival in the spinal cord.
Inflammatory components have been implicated in the
neurodegeneration associated with ALS [36]. As expected,
the injection procedure resulted in a local microglial and
Fig. 4 Effect of hydrogen peroxide (H2O2) on SOD1
G93A MN survival
in vitro. Survival of SOD1G93A MNs was reduced compared to SOD1WT
MNs under oxidative stress (a). Survival of SOD1G93A MNs increased
when co-cultured with bNCSCs (SOD1G93A MNs+ bNCSCs) compared
to when cultured alone (SOD1G93A MN) (b). Asterisks indicate level of
statistical significance by two-way ANOVA followed by Bonferroni
multiple comparison test (*** p < 0.001, ** p < 0.01, *p < 0.05). Data
shown is in mean± SEM of three independent experiments
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Fig. 5 Increased survival of SOD1G93A MN after co-implantation with
bNCSC to the spinal cord of mice. One week after implantation,
SOD1G93A MN co-implanted with bNCSC showed significantly
increased survival compared to SOD1G93A MN implanted alone.
Asterisks indicate the level of statistical significance by two-tailed
Student’s t-test (* p < 0.05). Data shown is in mean ± SEM of three
animals per condition (a). SOD1G93A MNs when implanted alone are
located as single cells in the spinal cord parenchyma (b). When
implanted together with bNCSCs, SOD1G93A MNs can be found both
spread out as single cells as well as in close proximity to bNCSCs (c). The
injection site showed increased immunoreactivity for GFAP and Iba1
following implantation of either SOD1G93A MN alone (d) or co-
implantation with bNCSCs (e). Arrows indicate bNCSCs differentiated
to GFAP positive cells (e). Scale bars: b,c 25 μm; d,e 10 μm for GFAP
and 20 μm for Iba1
Aggarwal et al.
astroglial response at the site of cell implantation, but this
response did not differ between the two experimental condi-
tions. However, when areas harboring implanted cells were
analyzed, immunoreactivity for host microglia/macrophages
and astrocytes appeared reduced where SOD1G93A and
bNCSCs were co-localized, suggesting that bNCSCs are able
to attenuate the local inflammatory response associated with
implanted SOD1G93A MNs. The survival support by bNCSCs
may initially rely on direct cell-cell interactions at the site of
cell implantation where bNCSCs and SOD1G93A MN precur-
sors intermingle during the injection procedure. However, the
presence of GFP+ MNs at a distance from bNCSCs and in the
vicinity of the central canal one week after implantation indi-
cates that some implanted SOD1G93A MN precursors rapidly
become independent of close contact with bNCSCs. Survival
of migrated SOD1G93A MNs may be supported by bNCSC-
derived diffusible molecules, such as vascular endothelial
growth factor (VEGF), brain-derived neurotrophic factor
(BDNF), glial-derived neurotrophic factor (GDNF), and cili-
ary neurotrophic factor (CNTF) [35], all of which have trophic
e f f e c t s on MNs [37 ] . bNCSC-d e r i v e d ma t r i x
metalloproteinase-2 and -9 (MMP-2 and -9) [36], which have
been implicated in cell migration [38, 39], may contribute to
the migratory capacity of implanted SOD1G93A MNs to the
spinal cord parenchyma and in some cases towards the central
canal (Supplemental Fig. 4). The ependyma which surrounds
this canal is a source of growth factors [40] and was previous-
ly designated as a stem cell region in the adult spinal cord [41].
Previous studies have shown that stem cells readily generate
neurons when transplanted into neurogenic areas of the adult
brain [42, 43]. The survival of SOD1G93A MN precursors in
the central canal area suggests that this is a region in the spinal
cord with neurogenic properties, which are beneficial for the
survival of implanted MN precursors.
Fig. 6 Transplanted bNCSCs might diminish the local glial response
following implantation. Spinal cord areas partially surrounded by
bNCSC transplants showed decreased immunoreactivity for GFAP (a,
inside) and Iba1 (b, inside) and a high number of co-implanted
SOD1G93A MN (a, b). Overviews show GFAP and Iba1 in blue, high
magnification confocal images show GFAP and Iba1 in white and cell
nuclei in blue for areas inside and outside the area of bNCSC
transplantation. Scale bars: a,b 25 μm for overviews and 10 μm for
high magnification images
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The ability of bNCSCs to promote vascularization of co-
implanted tissue [29] may also have contributed to improved
survival of co-implanted SOD1G93A MNs. Previous studies
have shown that ALS is associated with disruption of the
blood-CNS-barrier (B-CNS-B) [44–46], a process that can
contribute to the inflammatory response in areas affected by
ALS. An interesting aspect in this context is whether the
angiogenetic properties of bNCSCs in combination with their
preferential post-implantation differentiation to healthy
SOD1G93A resistant astrocytes may contribute to the forma-
tion of new blood vessels with an intact B-CNS-B in the
diseased spinal cord. Implantation of bNCSCs to animal
models of ALS may clarify the potential of these cells to
recover B-CNS-B.
In conclusion, we show that bNCSCs promote survival of
SOD1G93A MNs in vitro and in vivo after co-implantation to
the spinal cord. The beneficial effects by bNCSCs might be
due to their resistance to oxidative stress and their neurotroph-
ic and angiogenic support. These properties in combination
with their resistance to SOD1G93A aggregates make them in-
teresting candidates for further investigations on novel thera-
peutic approaches to achieve long-term neuroprotection in
animal models of ALS.
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